gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BCRXHealthcareBiotechnology

BioCryst Pharmaceuticals Inc (BCRX)

$8.24−3.85%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$8.57▲ 24.93% in range
Nov 3, 2025Low $6.24 · High $11.11Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

BioCryst Pharmaceuticals closed at $8.24 on Nov 4, down 3.85%, 25.8% below its 52-week closing high. Volume of 10.2M shares was 2.04× its 20-day average (well above normal).

Split-adjusted performance: +3.6% over one month, -6.7% over six months, +20.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $218.25M, up 33.6% from a year earlier, with a net margin of 35.9%.

Short interest was 26.6M shares at the Oct 15 settlement, down 3.3% from the prior report (10.9% of float, 5.8 days to cover).

Market cap$2.11B255.5M shares
Revenue · quarter$218.3M+33.6% YoY
Diluted EPS$0.30+1400.0% YoY
P/E · TTM—P/S 2.2×
Net margin35.9%Gross 98.2%
Dividend yieldNone
52-week range6.24 – 11.11−25.8% from high
Volume10.2M2.04× 20-day avg
Volatility · 60d44.3%Annualised
Short % of float10.9%5.8 days to cover
Net cash-$471.6MCash $352.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.6%1M +3.6%3M −11.4%6M −6.7%YTD +5.6%1Y +20.1%3Y +50.1%5Y −44.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum62
Revenue growth71
Net margin91
Value (low P/E)—
Size78

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short26.6M−3.3% vs prior
Days to cover5.8Settled Oct 15
% of float10.9%
Short vol. 10d35.9%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BCRXBioCryst Pharmaceuticals$8.24−3.85%−6.7%+33.6%35.9%—$2.11B
COAGHemab Therapeutics Holdings$45.09+4.62%————$2.11BCompare
VIRVir Biotechnology$11.77+4.90%+14.4%+19582.5%33.5%—$1.99BCompare
REPLReplimune Group$20.69+0.19%+501.5%———$1.96BCompare
RXRXRecursion Pharmaceuticals$3.88+5.43%+13.1%+258.5%−641.6%—$2.32BCompare
VCELVericel$45.48+10.68%+23.7%+22.5%2.8%96.2$2.33BCompare
ADMAADMA Biologics$10.48−5.67%+4.0%+2.0%30.4%13.9$2.35BCompare
MAZEMaze Therapeutics$33.38+3.50%+26.1%———$1.85BCompare
NVAXNovavax$10.65+10.02%+13.8%−76.3%−94.2%—$1.76BCompare

News about BioCryst Pharmaceuticals

All news →
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?Zacks Investment Research · 5d ago▲ PositiveBioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research · Oct 28, 2026NeutralBioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAEGlobeNewswire Inc. · Oct 21, 2026▲ PositiveBioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswire Inc. · Jun 12, 2026▲ PositiveBioCryst Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire Inc. · May 6, 2026▲ Positive

Quick answers

What does BioCryst Pharmaceuticals do?
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry.
What is BCRX's market cap?
$2.11B, based on the Nov 4 close of $8.24.
Does BioCryst Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BCRX is sold short?
26.6M shares, 10.9% of float, as of Oct 15, 2026.
What sector is BCRX in?
Healthcare, in the Biotechnology industry.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

HQ: Durham, NC435 employeesListed Mar 3, 1994biocryst.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology